지놈앤컴퍼니
Financials
Valuation Metrics
지놈앤컴퍼니's Market Cap is ₩1657B. At end of 2025 it was ₩3123B. Ranked #928 of 2,436 in KR market (top 38%), #443 of 1,649 on KOSDAQ (top 27%), #105 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 45%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 165.71B KRW | KR#928/2,436 Sec#105/234 |
| Revenue | 24.02B KRW | KR#2,092/2,436 Sec#148/234 |
| Net Income | -7.37B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 174.35B KRW | KR#1,373/2,436 Sec#105/234 |
| Net Assets | 114.23B KRW | KR#1,302/2,436 Sec#105/234 |
| Employees | 102 | KR#1,612/2,436 Sec#126/234 |
| Value | ||
| P/B | 1.45x | KR#1,762/2,436 Sec#125/234 |
| P/S | 6.90x | KR#2,210/2,436 Sec#149/234 |
| FCF Yield | -11.27% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -6.45% | KR#1,791/2,436 Sec#133/234 |
| ROA | -4.23% | KR#1,852/2,436 Sec#138/234 |
| Op. Margin | -119.19% | KR#2,324/2,436 Sec#179/234 |
| Revenue Growth | -8.99% | KR#1,842/2,436 Sec#170/234 |
| Financial Health | ||
| Debt Ratio | 152.63% | KR#1,223/2,436 Sec#140/234 |
| Total Debt | 23.64B KRW | KR#1,294/2,436 Sec#107/234 |
| FCF | -18.67B KRW | KR#1,885/2,436 Sec#178/234 |
| Cash | 47.13B KRW | KR#782/2,436 Sec#50/234 |
| Current Ratio | 1.49x | KR#1,317/2,436 Sec#144/234 |
| Performance | ||
| 1Y Return | 36.70% | KR#309/2,436 Sec#27/234 |
| 1M Return | -2.93% | KR#1,209/2,436 Sec#118/234 |
| From 52W High | -64.15% | KR#1,914/2,436 Sec#162/234 |
| 1Y MDD | -70.01% | KR#1,945/2,436 Sec#165/234 |
| Trading | ||
| Volume | 478,170 shares | KR#287/2,436 Sec#33/234 |
| Foreign Own. | 4.94% | KR#811/2,436 Sec#77/234 |
| Per Share | ||
| EPS | -142 KRW | KR—/2,436 Sec—/234 |
| BPS | 2,363 KRW | KR#1,944/2,436 Sec#158/234 |
Company Info
Established in 2015, this global new drug development specialized company went public on KOSDAQ in 2020 and subsequently acquired the management rights of List Labs, a US microbiome CDMO company. Leveraging its Genocle new drug development platform, it researches and develops anticancer drugs and microbiome medicines. The company also operates CDMO, microbiome cosmetics, and health functional food businesses, aiming for integrated pharmaceutical company growth through clinical data-based new drug development and technology transfer commercialization.